The number of mutation of genes BRCA1 and BRCA2 in Indian Breast Cancer Patients
Not Applicable
Completed
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2022/06/043293
- Lead Sponsor
- AstraZeneca Pharma India Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 305
Inclusion Criteria
1. Patients who are ready to provide written informed consent
2. Patients of both genders of > 18 years of age
3. Newly diagnosed breast cancer patients who may or may not have undergone primary surgery with or without radiotherapy, and who have not yet completed their first line of systemic therapy. First line therapy is defined as neo(adjuvant) chemotherapy/ hormonal therapy/HER2 targeted therapy.
Exclusion Criteria
1. Patients with breast cancer with HER2 IHC 2+, in whom in situ hybridization (ISH) is not done or not planned to be done.
2. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method